Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
U6 small nuclear RNA 1126, pseudogene (RNU6-1126P), is a processed pseudogene of the U6 small nuclear RNA (U6 snRNA) gene family in humans. U6 snRNA itself is a highly conserved, noncoding RNA component of the spliceosome, the cellular machinery that catalyzes the removal of introns from pre-mRNA during pre-mRNA splicing[3][1]. However, as a pseudogene, RNU6-1126P does not encode a functional RNA product and lacks a biological role in splicing or gene regulation. Such pseudogenes are typically generated by retrotransposition events and do not produce active biomolecules[2]. There is no evidence that RNU6-1126P serves as a therapeutic target, nor is it involved in disease, drug interactions, or known as a biomarker. Its only relevance is as an evolutionary remnant, reflecting the history of retrotransposition activity in the genome[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U6 small nuclear RNA 1126, pseudogene (RNU6-1126P).